{"id":"NCT01441440","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)","officialTitle":"A Randomized, Double-blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2011-09-27","resultsPosted":"2015-03-13","lastUpdate":"2021-01-28"},"enrollment":538,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"venlafaxine ER 75 mg/day (fixed dose)","otherNames":[]},{"type":"DRUG","name":"venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"venlafaxine ER 75 mg/day (fixed dose)","type":"EXPERIMENTAL"},{"label":"venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and venlafaxine ER 75 mg/day to 225 mg/day (flexible dose), compared to placebo. This study consists of 2 week screening phase, 8 week treatment phase and 2 week tapering phase. The follow-up visit will be evaluated after 2 weeks of last study medication dosing.","primaryOutcome":{"measure":"Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination","timeFrame":"Baseline, Week 8 or Early termination","effectByArm":[{"arm":"Placebo","deltaMin":-9.25,"sd":0.48},{"arm":"Venlafaxine 75 mg/Day Fixed","deltaMin":-10.76,"sd":0.5},{"arm":"Venlafaxine 75-225 mg/Day Flexible","deltaMin":-10.37,"sd":0.49}],"pValues":[{"comp":"OG000 vs OG001","p":"0.031"},{"comp":"OG000 vs OG002","p":"0.106"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":63,"countries":["Japan"]},"refs":{"pmids":["32912597","26513202"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2411263&StudyName=Venlafaxine%20ER%20Phase%203%20Study%20for%20Major%20Depressive%20Disorder%20%28MDD%29"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":183},"commonTop":["Nausea","Nasopharyngitis","Somnolence","Headache","Thirst"]}}